When tested in a mouse model of breast cancer, the doxorubicin-loaded nanoparticles caused fewer side effects than free ...

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery ...

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Race Oncology announced the successful and safe dosing of the first patient with a ...

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to a different device, you may be asked to login again with only ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

Sun Pharma's India business head, Kirti Ganorkar, will become the managing director on September 1, succeeding founder Dilip ...

Medicus Pharma submitted a product development plan to the FDA for an investigational new animal drug designation.

Doxorubucin is an effective therapeutic in cancer treatment, but it can cause cardiotoxicity and damage the mitochondrial machinery. A new patient-derived and mitochondria-rich human induced ...

In this study, laponite (LAP) nanodisks encapsulated with anticancer drug doxorubicin (DOX) at an exceptionally high loading efficiency (98.3 ± 0.77%) were used for tumor therapy applications. The ...

Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and ...